Opportunity in the Biomedical Roller Coaster
Even in this market meltdown, seasoned biotech innovators with decades of experience know that strong novel science in the hands of experienced teams will eventually succeed. We’re in a painful, protracted biotech market correction. The XBI index is down 39% YTD and 60% over the past 14 months. But I contend that this is not …